Chimerix (NASDAQ:CMRX - Get Free Report) issued its quarterly earnings data on Wednesday. The biopharmaceutical company reported ($0.25) EPS for the quarter, missing the consensus estimate of ($0.21) by ($0.04), Zacks reports. Chimerix had a negative net margin of 25,337.96% and a negative return on equity of 37.93%. During the same period in the previous year, the business posted ($0.24) EPS.
Chimerix Stock Performance
CMRX remained flat at $0.95 during trading on Thursday. 319,099 shares of the company's stock were exchanged, compared to its average volume of 385,212. The stock has a 50-day simple moving average of $1.05 and a two-hundred day simple moving average of $1.00. Chimerix has a twelve month low of $0.88 and a twelve month high of $1.57. The company has a market capitalization of $85.17 million, a P/E ratio of -1.04 and a beta of 1.13.
Wall Street Analyst Weigh In
Several equities analysts recently issued reports on CMRX shares. HC Wainwright reissued a "buy" rating and issued a $11.00 target price on shares of Chimerix in a research report on Friday, March 1st. StockNews.com raised shares of Chimerix from a "sell" rating to a "hold" rating in a research note on Monday, March 4th. Finally, Wedbush reaffirmed an "outperform" rating and issued a $6.00 price target on shares of Chimerix in a research note on Monday, February 12th.
Get Our Latest Research Report on Chimerix
Chimerix Company Profile
(
Get Free Report)
Chimerix, Inc, a biopharmaceutical company, develops medicines to improve and extend the lives of patients facing deadly diseases. Its pipeline products include ONC201 a program that is in Phase 3 clinical trial for treating patients with H3 K27M-mutant diffuse glioma, as well as in Phase 2 clinical trial for the treatment of rare neuroendocrine tumors; and ONC206, an imipridone, Dopamine Receptor D2 (DRD2) antagonist, and caseinolytic protease P (ClpP) agonist, which is in Phase 1 clinical trial for adult and pediatric patients with primary central nervous system tumors.
Featured Articles
Before you consider Chimerix, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Chimerix wasn't on the list.
While Chimerix currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio.
Get This Free Report
